These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17545529)

  • 21. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
    Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC
    Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients.
    Mylin AK; Abildgaard N; Johansen JS; Andersen NF; Heickendorff L; Standal T; Gimsing P; Knudsen LM
    Eur J Haematol; 2008 Apr; 80(4):310-7. PubMed ID: 18182077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.
    Mylin AK; Abildgaard N; Johansen JS; Heickendorff L; Kreiner S; Waage A; Turesson I; Gimsing P;
    Leuk Lymphoma; 2015; 56(9):2650-9. PubMed ID: 25573204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
    Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
    Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
    Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
    Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Windrichova J; Fuchsova R; Kucera R; Topolcan O; Fiala O; Finek J; Slipkova D; Karlikova M; Svobodova J
    Anticancer Res; 2016 Apr; 36(4):1973-8. PubMed ID: 27069189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease.
    Nøjgaard C; Johansen JS; Christensen E; Skovgaard LT; Price PA; Becker U;
    J Hepatol; 2003 Aug; 39(2):179-86. PubMed ID: 12873813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early detection and prognosis of ovarian cancer using serum YKL-40.
    Dupont J; Tanwar MK; Thaler HT; Fleisher M; Kauff N; Hensley ML; Sabbatini P; Anderson S; Aghajanian C; Holland EC; Spriggs DR
    J Clin Oncol; 2004 Aug; 22(16):3330-9. PubMed ID: 15310777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.
    Biggar RJ; Johansen JS; Smedby KE; Rostgaard K; Chang ET; Adami HO; Glimelius B; Molin D; Hamilton-Dutoit S; Melbye M; Hjalgrim H
    Clin Cancer Res; 2008 Nov; 14(21):6974-8. PubMed ID: 18980992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer.
    Roslind A; Knoop AS; Jensen MB; Johansen JS; Nielsen DL; Price PA; Balslev E
    Breast Cancer Res Treat; 2008 Nov; 112(2):275-85. PubMed ID: 18157633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients.
    Ueda M; Inaba M; Okuno S; Nagasue K; Kitatani K; Ishimura E; Shimizu M; Miki T; Kim M; Nishizawa Y
    Am J Kidney Dis; 2002 Oct; 40(4):802-9. PubMed ID: 12324916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.
    Høgdall EV; Johansen JS; Kjaer SK; Price PA; Christensen L; Blaakaer J; Bock JE; Glud E; Høgdall CK
    Oncol Rep; 2003; 10(5):1535-8. PubMed ID: 12883737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.
    Som A; Tu SM; Liu J; Wang X; Qiao W; Logothetis C; Corn PG
    Br J Cancer; 2012 Oct; 107(9):1547-53. PubMed ID: 23033003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer.
    Bi J; Lau SH; Lv ZL; Xie D; Li W; Lai YR; Zhong JM; Wu HQ; Su Q; He YL; Zhan WH; Wen JM; Guan XY
    Hum Pathol; 2009 Dec; 40(12):1790-7. PubMed ID: 19765801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.
    Cook RJ; Coleman R; Brown J; Lipton A; Major P; Hei YJ; Saad F; Smith MR
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3361-7. PubMed ID: 16740758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
    Dehn H; Høgdall EV; Johansen JS; Jørgensen M; Price PA; Engelholm SA; Høgdall CK
    Acta Obstet Gynecol Scand; 2003 Mar; 82(3):287-93. PubMed ID: 12694127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A variation in Bone Alkaline Phosphatase levels that correlates positively with bone loss and normal levels of aminoterminal propeptide of collagen I in girls with anorexia nervosa.
    Calero JA; Muñoz MT; Argente J; Traba ML; Méndez-Dávila C; García-Moreno C; de la Piedra C
    Clin Chim Acta; 1999 Jul; 285(1-2):121-9. PubMed ID: 10481928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease.
    La Montagna G; D'Angelo S; Valentini G
    J Rheumatol; 2003 Oct; 30(10):2147-51. PubMed ID: 14528508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.